Viatris Inc.

NASDAQ:VTRS

Drug Manufacturers - Specialty & Generic

Healthcare
$20.28 -2.29%

-$0.36 today

Market cap
$23.25B
Beta
0.90
P/E (TTM)
-59.9
EPS (TTM)
-$0.26
Dividend yield
3.12%
52W Low $8.63High $17.53

Volume 13.21M

Average 10.58M

VTRS Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Viatris Inc.NASDAQ: VTRS

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin narrows to -3.2%

Net margin was -3.2% in Q2 FY2026, down 3.0 pp from a year earlier. On a trailing-twelve-month basis it was -2.8%, up 21.8 pp year over year. Over 3 fiscal years it narrowed by 37.4 pp.

Context

  • Net margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 7 analysts of 20.5% for the fiscal year ending Dec 2026, up from -24.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-3.2%-8.2 pp QoQ
Last fiscal yearDec 2025
-24.6%-20.3 pp YoY
LTMJun 2026
-2.8%+21.8 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-3.0 pp+22.7 pp+25.8 pp
1 year-20.3 pp+45.0 pp+65.3 pp
3 years-37.4 pp+45.6 pp+83.0 pp
5 years+46.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-24.6%
Year-over-year change
-20.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How VTRS compares with its peers on the latest reported figures

  • VTRS's LTM Jun 2026 net margin of -2.8% is the 9th highest of the 10 companies compared; the peer median is 5.0%.
  • Its year-over-year change of +21.8 pp is the highest of 9, against a peer median of -6.5 pp.
  • Over three fiscal years its change of -37.4 pp compares with a peer median of +5.0 pp.
VTRS Competitors Peer median
Net Margin for VTRS and competitors
Company Period LTM level YoY 3-year change
HLNHaleon plcLTM Jun 202514.6% —+5.0 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202611.0% -8.5 pp-4.7 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 20269.7% +12.8 pp+24.0 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 20268.5% -8.7 pp-5.6 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 20265.0% +4.9 pp+8.3 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 20264.1% +5.0 pp+24.6 pp
OGNOrganon & Co.LTM Sep 20263.5% -4.5 pp-11.8 pp
ALKSAlkermes plcLTM Sep 2026-0.0% -22.3 pp+30.6 pp
VTRSViatris Inc.LTM Jun 2026-2.8% +21.8 pp-37.4 pp
BHCBausch Health Companies Inc.LTM Jun 2026-10.1% -11.1 pp+4.3 pp
Peer median (excluding VTRS) 5.0%-6.5 pp+5.0 pp

Competitors are the stored peer set for VTRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue17.89B16.26B15.43B14.74B14.3B
Cost of Revenue12.31B9.77B8.99B9.12B9.29B
Gross Profit5.58B6.5B6.44B5.62B5.01B
Gross Margin31.2%40.0%41.7%38.2%35.1%
Research & Development681M662.2M805.2M808.7M965.9M
Selling, General & Admin4.53B4.18B4.65B4.43B3.79B
Operating Expenses5.61B4.88B5.67B5.61B7.68B
Depreciation & Amortization4.51B3.03B2.74B2.71B2.8B
EBITDA4.48B6.43B3.52B2.64B(395.4M)
EBITDA Margin25.0%39.6%22.8%17.9%-2.8%
Operating Income(34M)1.61B766.2M10.1M(2.66B)
Operating Margin-0.2%9.9%5.0%0.1%-18.6%
Interest Income00000
Interest Expense636.2M592.4M573.1M550M471.3M
Other Income / Expenses(630.4M)1.2B(563.3M)(633.3M)(1B)
Income Before Tax(664.4M)2.81B202.9M(623.2M)(3.67B)
Pre-Tax Margin-3.7%17.3%1.3%-4.2%-25.6%
Income Tax Expense604.7M734.6M148.2M11M(150.1M)
Net Income(1.27B)2.08B54.7M(634.2M)(3.51B)
Net Margin-7.1%12.8%0.4%-4.3%-24.6%
EPS (Basic)(1.05)1.710.05(0.53)(3.00)
EPS (Diluted)(1.05)1.710.05(0.53)(3.00)
Weighted Avg Shares1.21B1.21B1.2B1.19B1.17B
Weighted Avg Shares (Diluted)1.21B1.22B1.21B1.19B1.17B

Viatris Inc.

NASDAQ:VTRS

Intrinsic Alpha fair value

Locked

Current Price

$20.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.